ALLMedicine™ Mesothelioma Center

Jan 27th, 2023 - Background Malignant pleural mesotheliomas (MPM) are aggressive cancers with a high predilection for intrapleural recurrences despite potentially curative resections. Pleural metastases and associated malignant pleural effusions (MPE) cause consid...

Jan 26th, 2023 - Background: Mutations involving BRCA1-Associated Protein-1 (BAP1), a nuclear deubiquitinase involved in epigenetic regulation of gene expression, DNA repair, and cellular energetics, have emerged as one of the most common somatic mutations in mali...

Jan 26th, 2023 - The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiatio...

Jan 25th, 2023 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Jan 25th, 2023 - The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another trea...

Dec 4th, 2021 - Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Popat S,Baas P,Faivre-Finn C,Girard N,Nicholson AG,|

Feb 5th, 2021 - Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in ...

Mar 27th, 2020 - Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.|2020|Kusamura S,Kepenekian V,Villeneuve L,Lurvink RJ,Govaerts K,|diagnosis,pathology,therapy,diagnosis,pathology,therapy,

Jul 29th, 2018 - Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE m...

Mar 9th, 2018 - Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.|2018|Kindler HL,Ismaila N,Hassan R,|diagnosis,therapy,diagnosis,therapy,diagnosis,therapy,

Jan 27th, 2023 - Background Malignant pleural mesotheliomas (MPM) are aggressive cancers with a high predilection for intrapleural recurrences despite potentially curative resections. Pleural metastases and associated malignant pleural effusions (MPE) cause consid...

Jan 26th, 2023 - Background: Mutations involving BRCA1-Associated Protein-1 (BAP1), a nuclear deubiquitinase involved in epigenetic regulation of gene expression, DNA repair, and cellular energetics, have emerged as one of the most common somatic mutations in mali...

Jan 26th, 2023 - The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiatio...

Jan 25th, 2023 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Jan 25th, 2023 - The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another trea...

Jan 11th, 2023 - Almost one-third of patients undergoing omentectomy for peritoneal metastases had occult omental metastases, supporting routine omentectomy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), authors of a retr...

Oct 27th, 2022 - The FDA has granted an orphan drug designation (ODD) to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.1 SynKIR-110 is a next-generation cell therapy desi...

Oct 18th, 2022 - The targeted radiotherapy candidate lutetium-177-FAP-2286 (177Lu-FAP-2286) produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase ...

Oct 14th, 2022 - A landmark essay by the late eminent evolutionary biologist Stephen J. Gould, PhD, entitled The Median Isn’t the Message serves as an excellent opening for this commentary. Gould, after receiving a diagnosis of primary peritoneal mesothelioma, wha...

Oct 6th, 2022 - (Reuters) - A U.S. bankruptcy judge has blocked New Mexico and Mississippi from pursuing lawsuits accusing Johnson & Johnson of misleading consumers about the safety of its talc products, such as its baby powder, for now. U.S. Bankruptcy Judge Mic...